Contrast-enhanced Radiotherapy Research Articles

Hafnium Complexes as Contrast Media and Dose Enhancing Agents for Radiology and Contrast-Enhanced Radiotherapy

Hafnium Complexes as Contrast Media and Dose Enhancing Agents for Radiology and Contrast-Enhanced Radiotherapy

Metal Nanoparticles as Radiosensitizers for Cancer Radiotherapy in Vivo

Metal nanoparticles are capable of enhancing the destructive effect of ionizing radiation on biological
 tissue, which allows them to be used as radiosensitizers for improving the efficacy of cancer radiotherapy. The most promising nanoparticles are those with a high atomic number (Z>52), since they can
 serve both as dose-enhancing agents for contrast-enhanced radiotherapy and as contrast media for
 computed tomography. Due to the high metal content in each particle and the ability to selectively accumulate in tumor tissue, nanoscale agents can deliver more metal atoms to the tumor compared to
 low-molecular compounds. At present, only two metal nanoparticle agents (NBTXR3 and AGuIX) are
 undergoing clinical trials as radiosensitizers. However, a wide range of nanoparticles with different
 composition and structure is being extensively studied in laboratory animals. This review summarizes
 the results of in vivo studies where nanoparticles containing gold, bismuth or gadolinium were used in
 combination with external photon irradiation in order to inhibit the growth of model tumors in small
 laboratory animals.

Elevated Coronary Artery Calcium Quantified by a Validated Deep Learning Model From Lung Cancer Radiotherapy Planning Scans Predicts Mortality.

Coronary artery calcium (CAC) quantified on computed tomography (CT) scans is a robust predictor of atherosclerotic coronary disease; however, the feasibility and relevance of quantitating CAC from lung cancer radiotherapy planning CT scans is unknown. We used a previously validated deep learning (DL) model to assess whether CAC is a predictor of all-cause mortality and major adverse cardiac events (MACEs). Retrospective analysis of non-contrast-enhanced radiotherapy planning CT scans from 428 patients with locally advanced lung cancer is performed. The DL-CAC algorithm was previously trained on 1,636 cardiac-gated CT scans and tested on four clinical trial cohorts. Plaques ≥ 1 cubic millimeter were measured to generate an Agatston-like DL-CAC score and grouped as DL-CAC = 0 (very low risk) and DL-CAC ≥ 1 (elevated risk). Cox and Fine and Gray regressions were adjusted for lung cancer and cardiovascular factors. The median follow-up was 18.1 months. The majority (61.4%) had a DL-CAC ≥ 1. There was an increased risk of all-cause mortality with DL-CAC ≥ 1 versus DL-CAC = 0 (adjusted hazard ratio, 1.51; 95% CI, 1.01 to 2.26; P = .04), with 2-year estimates of 56.2% versus 45.4%, respectively. There was a trend toward increased risk of major adverse cardiac events with DL-CAC ≥ 1 versus DL-CAC = 0 (hazard ratio, 1.80; 95% CI, 0.87 to 3.74; P = .11), with 2-year estimates of 7.3% versus 1.2%, respectively. In this proof-of-concept study, CAC was effectively measured from routinely acquired radiotherapy planning CT scans using an automated model. Elevated CAC, as predicted by the DL model, was associated with an increased risk of mortality, suggesting a potential benefit for automated cardiac risk screening before cancer therapy begins.

A proof of concept kilovoltage intensity modulated radiotherapy platform for the treatment of glioblastoma multiforme

Purpose: To develop a compact, proof-of-concept kilovoltage intensity modulated radiotherapy platform to deliver contrast-enhanced radiotherapy (CERT). Methods: The proof-of-concept requirements were threefold: (i) develop a compact means to generate a kilovoltage x-ray broadbeam capable of targeting the K-edge of heavy metal contrast, (ii) investigate the potential clinical application of such a beam in silico, and (iii) construct a limited working prototype of the platform to identify weaknesses in the approach. The x-ray broadbeam was created with a standard kilovoltage x-ray tube heavily filtered with 0.156 mm tungsten. Depth dose and treatment characteristics of the beam were investigated using GEANT4 Monte Carlo framework. The working prototype included a miniaturized multi-rod collimator (MRC) constructed with tungsten carbide rods, 3D-printed gear rack, and an in-house GUI/microprocessor assembly. Measurements of simulated treatments were made with EBT3 radiochromic film. Results: Monte Carlo simulations of pseudo-clinical treatments on a homogeneous spherical Lucite phantom produced dose distributions that indicated surface dose was less than target dose. When simulated-bone was added to the calculations, dose-to-bone was found to be the probable limiting factor in clinical treatment. Nevertheless, when iodine contrast enhancement was accounted for, dose was escalated in the tumor compared to standard megavoltage treatments even with dose-to-bone limitations. Experimentally, after commissioning the MRC and calibrating the radiochromic film, surface dose was compared to maximum dose measured on each film. Surface dose measurements were higher than those in a megavoltage beam, but below the skin toxicity threshold. Dose at depth was reasonable despite increased beam attenuation at these energies from photoelectric interactions in bone. IMRT and non-coplanar dose falloffs around the target were steeper than kV 3D conformal dose falloff. Conclusions: The compact kilovoltage treatment platform presented here proved clinically feasible in both simulation and measurement. It is reasonable to pursue this modality further as a potential CERT platform.

Radiation therapy planning using MRI-CT fusion in dogs and cats with brain tumors.

Volume definition is a delicate step within the radiation treatment planning process and the precision of defining the volumes to irradiate is important for the success of the radiation treatment. Traditionally, radiation plans are created using computed tomography (CT) studies. Due to its different mechanism of action, magnetic resonance imaging (MRI) is more sensitive for detection of brain lesions. Therefore, using fused images of both imaging modalities should result in a more precise definition of the volumes to irradiate. The feasibility to fuse CT and MRI studies performed at different institutions was tested to subsequently analyse the influence of the fused images on target volume definition. Fourteen dogs and four cats with brain lesions having MR- and CT-imaging were included. Contrast-enhanced radiotherapy planning CT scans were fused to T1-weighted post-contrast and T2-weighted MRI scans. The gross tumor volume (GTV), the clinical tumor volume (CTV) and the planning target volume (PTV) were delineated on CT- and MRI studies. CT and MRI volumes were compared with regard to volumetric and spatial differences. The mean GTV was larger on MRI than on CT (2.15 vs.1.54 cm3). Also the mean CTV was larger on MRI than on CT (5.34 vs. 4.38 cm3). Consequently, the mean PTV was larger on MRI than on CT (14.20 vs. 10.82 cm3) as well. None of the differences in defined volumes were significant. Fusion images were accepted showing mean errors of 1.32 mm (mean error) and 1.73 mm (maximal error). CT-MRI fusion was feasible especially when defined, reliable, and consistent anatomic landmarks were used as registration points. Volumetric differences between CT and MRI were insignificant. In general, GTV and CTV were easier identified on MRI.

Combined Megavoltage and Contrast-Enhanced Radiotherapy as an Intrafraction Motion Management Strategy in Lung SBRT.

Using Monte Carlo simulation and a realistic patient model, it is shown that the volume of healthy tissue irradiated at therapeutic doses can be drastically reduced using a combination of standard megavoltage and kilovoltage X-ray beams with a contrast agent previously loaded into the tumor, without the need to reduce standard treatment margins. Four-dimensional computed tomography images of 2 patients with a centrally located and a peripherally located tumor were obtained from a public database and subsequently used to plan robotic stereotactic body radiotherapy treatments. Two modalities are assumed: conventional high-energy stereotactic body radiotherapy and a treatment with contrast agent loaded in the tumor and a kilovoltage X-ray beam replacing the megavoltage beam (contrast-enhanced radiotherapy). For each patient model, 2 planning target volumes were designed: one following the recommendations from either Radiation Therapy Oncology Group (RTOG) 0813 or RTOG 0915 task group depending on the patient model and another with a 2-mm uniform margin determined solely on beam penumbra considerations. The optimized treatments with RTOG margins were imparted to the moving phantom to model the dose distribution that would be obtained as a result of intrafraction motion. Treatment plans are then compared to the plan with the 2-mm uniform margin considered to be the ideal plan. It is shown that even for treatments in which only one-fifth of the total dose is imparted via the contrast-enhanced radiotherapy modality and with the use of standard treatment margins, the resultant absorbed dose distributions are such that the volume of healthy tissue irradiated to high doses is close to what is obtained under ideal conditions

Evaluation of absorbed dose distribution in melanoma B16F10 during contrast enhanced radiotherapy with intratumoral administration of dose-enhancing agent

Contrast-enhanced radiotherapy (CERT) is a binary treatment modality in which the absorbed radiation dose is not only determined by the parameters of the external radiation source but also affected by the concentration of a dose-enhancing agent (DEA) in the studied object. In this work we assessed the distribution of the absorbed dose in a murine B16F10 melanoma injected with a single dose of an aqueous Bi-DTPA solution. The mice were exposed to a single fraction of X-ray irradiation for 28.5 min. In vivo measurements of DEA concentrations were done on a micro-CT scanner using the radiopacity values of malignant tissues from the obtained CT images. We found that the presence of DEA enhanced the absorbed dose more than twofold in 6% of the tumor volume; in 29% of the tumor volume the absorbed dose increased more than onefold. The tumor growth delay time calculated for our model was 0.76 days (we only accounted for the damage caused directly by radiation), whereas in our previous research study tumor growth delay was 10 days. This discrepancy may indicate that in the tumors exposed to contrast-enhanced radiotherapy growth delay results from both the damage directly caused by radiation and other antitumor mechanisms.

Возможность проведения фотон-захватной терапии с использованием 6 МВ фотонного излучения

Возможность проведения фотон-захватной терапии с использованием 6 МВ фотонного излучения

Absolute Perfusion Measurements and Associated Iodinated Contrast Agent Time Course in Brain Metastasis: A Study for Contrast-Enhanced Radiotherapy

Contrast-enhanced radiotherapy is an innovative treatment that combines the selective accumulation of heavy elements in tumors with stereotactic irradiations using medium energy X-rays. The radiation dose enhancement depends on the absolute amount of iodine reached in the tumor and its time course. Quantitative, postinfusion iodine biodistribution and associated brain perfusion parameters were studied in human brain metastasis as key parameters for treatment feasibility and quality. Twelve patients received an intravenous bolus of iodinated contrast agent (CA) (40 mL, 4 mL/s), followed by a steady-state infusion (160 mL, 0.5 mL/s) to ensure stable intratumoral amounts of iodine during the treatment. Absolute iodine concentrations and quantitative perfusion maps were derived from 40 multislice dynamic computed tomography (CT) images of the brain. The postinfusion mean intratumoral iodine concentration (over 30 minutes) reached 1.94 ± 0.12 mg/mL. Reasonable correlations were obtained between these concentrations and the permeability surface area product and the cerebral blood volume. To our knowledge, this is the first quantitative study of CA biodistribution versus time in brain metastasis. The study shows that suitable and stable amounts of iodine can be reached for contrast-enhanced radiotherapy. Moreover, the associated perfusion measurements provide useful information for the patient recruitment and management processes.

Feasibility of kilovoltage x‐ray energy modulation by gaseous media and its application in contrast‐enhanced radiotherapy

To present a method to modulate the energy contents of a kilovoltage x-ray beam that makes use of a gas as the modulating medium. The method is capable of producing arbitrary x-ray spectra by varying the pressure of the modulating gas and the peak kilovoltage (kVp) of the x-ray beams whose energy is being modulated. An aluminum chamber was machined with a 0.5 cm wall thickness, designed to withstand pressures of more than 80 atm. A pressure sensor and electrovalves were used to monitor and regulate the gas pressure. Argon was used as the modulating gas. A CdTe spectrometer was used to measure x-ray spectra for different combinations of kVp and gas pressure, thus obtaining a set of basis x-ray functions. An arbitrary x-ray spectrum can then be formed by the linear combination of such basis functions. In order to show one possible application of the modulation method, a contrast-enhanced radiotherapy prostate treatment was optimized with respect to the x-ray beam energy, without restrictions on the possible shape of the resultant x-ray spectra. The x-ray spectra basis functions obtained display a smooth and gradual variation of their average energy as a function of the gas pressure for a given kVp, sometimes in the order of 1 or 2 keV. This gradual variation would be difficult to obtain with a conventional aluminum or copper filters, as the change in thickness necessary to reproduce the data presented would be in the order of micrometers, making necessary the use of a large number of such filters. Using the modulation method presented here, the authors were able to reconstruct the optimized x-ray spectra from the measured basis functions, for different optimization objectives. A method has been developed that allows for the controlled modulation of the energy contents of kilovoltage x-ray spectra. The method has been shown to be able to reproduce spectra of arbitrary shape, such as those obtained from the optimization of contrast-enhanced radiotherapy. The method may have other applications as well, such as in the precise matching of diagnostic x-ray catalog spectra.

Monte Carlo modeling of converging small-field contrast-enhanced radiotherapy of prostate

Radiation therapy using a kilovoltage X-ray source to irradiate a target previously loaded with a radiological contrast agent, contrast-enhanced radiotherapy (CERT), has been shown both theoretically and in a preliminary experimental study to represent a potential alternative to high-energy treatments. It has also been shown, however, to produce an integral dose that can be up to twice that resulting from a conventional megavoltage treatment. In this work, using a realistic patient model and Monte Carlo simulation, a CERT prostate treatment plan is designed that makes use of a plurality of small circular beams aimed at the target in such a way as to minimize the radiological trajectory to the target volume. Gold nanoparticles are assumed to be the contrast agent. Two cases are examined, one with a concentration level in the target of 10 mg-Au per gram of tissue and the second with a concentration of 3 mg-Au per gram of tissue in the target. A background concentration of 1 mg of contrast agent per gram of tissue was assumed everywhere else in both cases. The Cimmino feasibility algorithm was then used to find each beam weight in order to obtain the prescribed target dose, set at 72 Gy to 100% of the tumor volume. It is shown that the approach using the small circular fields, a radiosurgery treatment, produces treatment plans with excellent absorbed dose distributions while at the same time it reduces by up to 60% the non-tumor integral dose imparted to the irradiated subject. A brief discussion on the technology necessary to clinically implement this treatment modality is also presented.

Monte Carlo modeling and optimization of contrast-enhanced radiotherapy of brain tumors

Contrast-enhanced radiotherapy involves the use of a kilovoltage x-ray beam to impart a tumoricidal dose to a target into which a radiological contrast agent has previously been loaded in order to increase the x-ray absorption efficiency. In this treatment modality the selection of the proper x-ray spectrum is important since at the energy range of interest the penetration ability of the x-ray beam is limited. For the treatment of brain tumors, the situation is further complicated by the presence of the skull, which also absorbs kilovoltage x-ray in a very efficient manner. In this work, using Monte Carlo simulation, a realistic patient model and the Cimmino algorithm, several irradiation techniques and x-ray spectra are evaluated for two possible clinical scenarios with respect to the location of the target, these being a tumor located at the center of the head and at a position close to the surface of the head. It will be shown that x-ray spectra, such as those produced by a conventional x-ray generator, are capable of producing absorbed dose distributions with excellent uniformity in the target as well as dose differential of at least 20% of the prescribed tumor dose between this and the surrounding brain tissue, when the tumor is located at the center of the head. However, for tumors with a lateral displacement from the center and close to the skull, while the absorbed dose distribution in the target is also quite uniform and the dose to the surrounding brain tissue is within an acceptable range, hot spots in the skull arise which are above what is considered a safe limit. A comparison with previously reported results using mono-energetic x-ray beams such as those produced by a radiation synchrotron is also presented and it is shown that the absorbed dose distributions rendered by this type of beam are very similar to those obtained with a conventional x-ray beam.

Treatment planning considerations in contrast-enhanced radiotherapy: energy and beam aperture optimization

It has been shown that the use of kilovoltage x-rays in conjunction with a contrast agent incorporated into the tumor can lead to acceptable treatment plans with regard to the absorbed dose distribution produced in the target as well as in the tissue and organs at risk surrounding it. In this work, several key aspects related to the technology and irradiation techniques necessary to clinically implement this treatment modality are addressed by means of Monte Carlo simulation. The Zubal phantom was used to model a prostate radiotherapy treatment, a challenging site due to the depth of the prostate and the presence of bony structures that must be traversed by the x-ray beam on its way to the target. It is assumed that the concentration levels of the enhancing agent present in the tumor are at or below 10 mg per 1 g of tissue. The Monte Carlo code PENELOPE was used to model a commercial x-ray tube having a tungsten target. X-ray energy spectra for several combinations of peak electron energy and added filtration were obtained. For each energy spectrum, a treatment plan was calculated, with the PENELOPE Monte Carlo code, by modeling the irradiation of the patient as 72 independent conformal beams distributed at intervals of 5° around the phantom in order to model a full x-ray source rotation. The Cimmino optimization algorithm was then used to find the optimum beam weight and energy for different treatment strategies. It is shown that for a target dose prescription of 72 Gy covering the whole tumor, the maximum rectal wall and bladder doses are kept below 52 Gy for the largest concentration of contrast agent of 10 mg per 1 g of tissue. It is also shown that concentrations of as little as 5 mg per 1 g of tissue also render dose distributions with excellent sparing of the organs at risk. A treatment strategy to address the presence of non-uniform distributions of the contrast agent in the target is also modeled and discussed.

A Monte Carlo Comparison of Three Different Media for Contrast Enhanced Radiotherapy of the Prostate

Contrast-enhanced radiotherapy makes use of a kilovoltage X-ray beam, either from a diagnostic X-ray tube or modified megavoltage linear accelerator, in conjunction with a high-Z contrast medium deposited into the target volume to enhance the absorption of radiation. In this work, using the Monte Carlo code PENELOPE and the voxelized Zubal phantom to model a prostate radiotherapy treatment, a comparison between the physical absorbed dose distributions rendered by three different enhancing agents namely bismuth, gadolinium, and iodine is performed. It is assumed that there exists a concentration of 10 mg of enhancing agent per 1 g of tissue in the target volume while in the background a concentration of 1.5 mg per 1 g of tissue is present. The X-ray beam energy spectrum was obtained by means of Monte Carlo simulation of a tungsten target upon which a 220 keV mono-energetic electron pencil beam is made to impinge, and the resultant photon beam is heavily filtrated by 0.2 cm of copper. The treatment delivery is simulated as a 3608 arc collimated to conform to the target from every direction. Cumulative dose-volume histograms and isodose curves are presented for the target as well as five organs-at-risk, namely rectal wall, bladder, femoral heads, skin, and bone marrow. It is shown that under these conditions clinically acceptable treatment plans are obtained for all three contrast agents. A 72 Gy dose to 100% of the target volume results in maximum absorbed doses to the above mentioned organs-at-risk of 65, 56, 44, 32 and 65 Gy respectively when bismuth is used as the contrast agent, but the results obtained with gadolinium follow closely.

Treatment plans optimization for contrast‐enhanced synchrotron stereotactic radiotherapy

Synchrotron stereotactic radiotherapy (SSRT) is a treatment that involves the targeting of high-Z elements into tumors followed by stereotactic irradiation with monochromatic x-rays from a synchrotron source, tuned at an optimal energy. The irradiation geometry, as well as the secondary particles generated at a higher yield by the medium energy x-rays on the high-Z atoms (characteristic x-rays, photoelectrons, and Auger electrons), produces a localized dose enhancement in the tumor. Iodine-enhanced SSRT with systemic injections of iodinated contrast agents has been successfully developed in the past six years in the team, and is currently being transferred to clinical trials. The purpose of this work is to study the impact on the SSRT treatment of the contrast agent type, the beam quality, the irradiation geometry, and the beam weighting for defining an optimized SSRT treatment plan. Theoretical dosimetry was performed using the MCNPX particle transport code. The simulated geometry was an idealized phantom representing a human head. A virtual target was positioned in the central part of the phantom or off-centered by 4 cm. The authors investigated the dosimetric characteristics of SSRT for various contrast agents: Iodine, gadolinium, and gold; and for different beam qualities: Monochromatic x-ray beams from a synchrotron source (30-120 keV), polychromatic x-ray beams from an x-ray tube (80, 120, and 180 kVp), and a 6 MV x-ray beam from a linear accelerator. Three irradiation geometries were studied: One arc or three noncoplanar arcs dynamic arc therapy, and an irradiation with a finite number of beams. The resulting dose enhancements, beam profiles, and histograms dose volumes were compared for iodine-enhanced SSRT. An attempt to optimize the irradiation scheme by weighing the finite x-ray beams was performed. Finally, the optimization was studied on patient specific 3D CT data after contrast agent infusion. It was demonstrated in this study that an 80 keV beam energy was a good compromise for treating human brain tumors with iodine-enhanced SSRT, resulting in a still high dose enhancement factor (about 2) and a superior bone sparing in comparison with lower energy x-rays. This beam could easily be produced at the European Synchrotron Radiation Facility medical beamline. Moreover, there was a significant diminution of dose delivered to the bone when using monochromatic x-rays rather than polychromatic x-rays from a conventional tube. The data showed that iodine SSRT exhibits a superior sparing of brain healthy tissue in comparison to high energy treatment. The beam weighting optimization significantly improved the treatment plans for off-centered tumors, when compared to nonweighted irradiations. This study demonstrated the feasibility of realistic clinical plans for low energy monochromatic x-rays contrast-enhanced radiotherapy, suitable for the first clinical trials on brain metastasis with a homogeneous iodine uptake.

Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors

Radiotherapy using kilovoltage x-rays in conjunction with contrast agents incorporated into the tumor, gold nanoparticles in particular, could represent a potential alternative to current techniques based on high-energy linear accelerators. In this paper, using the voxelized Zubal phantom in conjunction with the Monte Carlo code PENELOPE to model a prostate cancer treatment, it is shown that in combination with a 360° arc delivery technique, tumoricidal doses of radiation can be delivered to deep-seated tumors while still providing acceptable doses to the skin and other organs at risk for gold concentrations in the tumor within the range of 7–10 mg-Au per gram of tissue. Under these conditions and using a x-ray beam with 90% of the fluence within the range of 80–200 keV, a 72 Gy physical absorbed dose to the prostate can be delivered, while keeping the rectal wall, bladder, skin and femoral heads below 65 Gy, 55 Gy, 40 Gy and 30 Gy, respectively. However, it is also shown that non-uniformities in the contrast agent concentration lead to a severe degradation of the dose distribution and that, therefore, techniques to locally quantify the presence of the contrast agent would be necessary in order to determine the incident x-ray fluence that best reproduces the dosimetry obtained under conditions of uniform contrast agent distribution.

Treatment planning for a synchrotron-based radiotherapy modality

Contrast enhanced radiotherapy (CERT) achieves biologically localised dose enhancement through the preferential uptake of high- Z media by the tumour cells. A treatment planning software originally developed for boron neutron capture therapy (BNCT) has been developed to evaluate treatment plans for CERT. A realistic test case of a brain tumour based on actual CT scans was used to calculate dose distributions with and without the presence of an iodinated contrast medium. An enhancement of dose was observed at all depths with the introduction of iodine and the corresponding dose enhancement factors were calculated for various concentrations.

Radiochromic film dosimetry of contrast-enhanced radiotherapy (CERT)

Contrast-enhanced radiotherapy (CERT) employs elevated concentrations of high-Z contrast media in targets to dramatically increase the absorbed dose of radiation relative to the surrounding tissues. However, it is difficult to measure the dose enhancement with routine clinical instruments because the photoelectrons and Auger electrons produced by the interaction of kilovoltage x-rays with the contrast agent travel extremely short distances. We have developed a technique utilizing unlaminated radiochromic film to measure the maximum dose enhancement factor attainable in solutions of contrast agent with iodine concentrations ranging from 0% to 37% (w/v). The films were also used to simultaneously measure the dose enhancement and beam attenuation through solutions containing 0%, 5% and 10% iodine (w/v). These depth–dose measurements were made in phantoms representing 3 cm targets located 0 and 4.8 cm deep in acrylic. Higher concentrations of contrast yielded greater dose enhancement and target-to-surface dose ratios, but caused more rapid attenuation of the beam as it traversed the target. The dose distribution across the entire target could be improved by employing multiple beams. These results, using concentrations of contrast that are clinically achievable by intratumoural injection, illustrate the potential of CERT for the specific delivery of high doses of radiation to targets at depth.

Dosimetric and microdosimetric study of contrast-enhanced radiotherapy with kilovolt x-rays

Kilovolt x-rays are clearly suboptimal compared to MV photon beams for radiotherapy of deep-seated tumours because of the increased attenuation in tissue, causing a rapid dose fall-off. This picture could change drastically when tumours can be labelled with contrast medium, containing high atomic number elements. This causes a significant dose enhancement to the tumour by exploiting the high cross sections for the photo-electric effect for kV x-rays. In this work, we have investigated the dosimetric and microdosimetric characteristics of kV contrast-enhanced radiation therapy (CERT) for different photon energies, contrast-medium concentrations and types (I and Gd). Two idealized patient treatment plans (head and lung) for irradiation with CT-arc beams were calculated. It is shown that the dose enhancement in tumours can be highly significant (up to about sixfold for realistic 80–120 kVp x-ray spectra and an iodine concentration of 50 mg ml−1) but that dose homogeneity in the tumour depends on photon energy, contrast-medium concentration and type, and irradiation scheme. An attempt to optimize the irradiation scheme is discussed. The microdosimetric study of the dose mean lineal energy shows that radiation quality changes in the contrast-medium-labelled region compared to homogeneous tissue are fairly small and limited to 10%. It is concluded that kV-CERT is a promising radiotherapy technique, provided contrast medium can be delivered reliably to tumours.